Form 4 for IMRX Immuneering Corp
Accepted 2022-03-01 00:00:00 ET · period of report 2022-02-28 · accession 0001415889-22-002061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-01 | 2022-02-28 | IMRX | Zeskind Benjamin J. | Pres AND CEO, Dir, 10% | M - OptEx | $3.01 | +2,000 | 2.25M | +0.1% | +$6,020 |
| D | 2022-03-01 | 2022-02-28 | IMRX | Zeskind Benjamin J. | Pres AND CEO, Dir, 10% | M - OptEx | $0.00 | -2,000 | 208.0K | -1.0% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-02-28 | M | A | 2,000 | $3.01 | 2,254,352 | D | — | — | |
| 2 | Derivative | Stock Option | 2022-02-28 | M | D | 2,000 | $0.00 | 208,000 | D | $3.01 · — to 2029-12-15 | 2,000 Class A Common Stock | (F2) The option has fully vested and is currently exercisable. |